Transitional Cell Carcinoma

A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence. (Stedman, 25th ed)

Also Known As:

Networked: 3441 relevant articles (146 outcomes, 461 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Urinary Bladder Neoplasms (Bladder Cancer)
3.	Neoplasm Metastasis (Metastasis)
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma)
5.	Carcinoma in Situ

Experts

1.	Lerner, Seth P: 24 articles (02/2013 - 03/2002)
2.	Stein, John P: 23 articles (11/2009 - 07/2003)
3.	Shariat, Shahrokh F: 23 articles (07/2008 - 03/2002)
4.	Skinner, Donald G: 17 articles (11/2009 - 07/2003)
5.	Lotan, Yair: 17 articles (07/2008 - 01/2002)
6.	Sagalowsky, Arthur I: 17 articles (03/2008 - 03/2004)
7.	Cai, Jie: 15 articles (11/2009 - 07/2003)
8.	Knapp, Deborah W: 13 articles (08/2015 - 01/2002)
9.	Sonpavde, Guru: 13 articles (12/2014 - 02/2006)
10.	Miranda, Gus: 13 articles (05/2009 - 09/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Transitional Cell Carcinoma:

1.	Cisplatin (Platino)FDA LinkGeneric 04/01/1978 - "These promising results seem to indicate the high degree of effectiveness of cis-diamminedichloroplatinum against transitional cell carcinoma of the bladder." 11/01/1996 - "To determine whether cisplatin administered at a dosage of 60 mg/m2 of body surface area, IV, every 21 days, would induce remission of transitional cell carcinoma of the urinary bladder in dogs. " 09/01/2010 - "First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?" 01/01/2007 - "Recent studies have demonstrated the effectiveness of cisplatin-based combinations in patients with advanced transitional cell carcinoma(TCC) of the urothelium. " 10/01/2006 - "Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group."
2.	gemcitabineFDA Link 01/01/2005 - "Our experience has shown the good tolerability and potential efficacy of intravesical gemcitabine against recurrent transitional cell carcinoma of the bladder. " 06/20/2006 - "The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder. " 09/01/2014 - "Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial." 09/01/2009 - "Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study." 06/20/2006 - "Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder."
3.	Doxorubicin (Adriamycin)FDA LinkGeneric 01/01/1984 - "We conclude that intravesical doxorubicin is tolerated well and is effective in the management of multiple recurrent superficial transitional cell carcinoma of the bladder." 05/01/2005 - "To evaluate the efficacy of adjuvant intravesical doxorubicin in superficial transitional cell carcinoma of the urinary bladder on long-term follow-up. " 07/01/2003 - "We studied whether p53 status has any predictive value on the outcome of intravesical adriamycin (ADR) instillation for superficial transitional cell carcinoma (TCC) of the bladder. " 07/01/2003 - "P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder." 10/24/1991 - "Patients with rapidly recurrent (stage Ta and T1) or in situ transitional-cell carcinoma of the bladder were randomly assigned to receive either doxorubicin administered intravesically or bacille Calmette-Guérin (BCG) administered both intravesically and percutaneously. "
4.	Mitomycin (Mitomycin-C)FDA LinkGeneric 10/01/1987 - "Intravesical mitomycin C is an effective agent for treatment of superficial transitional cell carcinoma of the bladder. " 08/01/2005 - "Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma." 05/01/1989 - "Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder." 01/01/1998 - "This in vitro study aimed to investigate the cytotoxic activity of 7-N-(2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl)-mitomycin C (KW-2149) versus mitomycin C (MMC) against cell lines from human transitional cell carcinoma (TCC). " 01/01/1988 - "In a prospective and randomized trial, 31 patients with superficial and/or CIS transitional cell carcinoma were treated by complete transurethral resection of all visible tumours, followed by instillation of 40 mg mitomycin C (MMC). "
5.	Carboplatin (JM8)FDA LinkGeneric 01/01/1996 - "Carboplatin monochemotherapy in elderly patients with nonoperable transitional cell carcinoma of the bladder: a two-stage, phase II study." 12/01/1989 - "This study indicated the low effectiveness of single agent carboplatin in transitional cell carcinoma of the urinary bladder." 12/01/1989 - "Twenty-five previously untreated patients with measurable locally advanced and/or metastatic transitional cell carcinoma of the urinary bladder were included in a phase II study with carboplatin. " 12/01/1989 - "Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder." 09/01/1997 - "Fourteen dogs with histologically-confirmed transitional cell carcinoma (TCC) of the urinary bladder were treated with 300 mg/m2 carboplatin every 3 weeks. "
6.	Methotrexate (Mexate)FDA LinkGeneric 05/01/1993 - "A total of 22 patients with superficial transitional cell carcinoma of the bladder, uncontrolled cystoscopically and unsuitable for or having failed intravesical therapy, received 50 mg. oral methotrexate per week for 12 months. " 05/01/1993 - "Oral methotrexate for superficial transitional cell carcinoma of the bladder." 01/01/1986 - "Twenty-one patients with superficial transitional cell carcinoma of the bladder received a total of 121 doses of intravesical methotrexate (MTX) at 11 different concentrations of drug, ranging from 40 mg/m2 (mean concentration of 2.9 X 10(-3) M) to 500 mg/m2 (4.9 X 10(-2) M). " 06/01/1985 - "Twenty-four patients with previously untreated T1 transitional cell carcinoma of the bladder were treated with oral methotrexate 50 mg weekly for 18 months. " 06/01/1985 - "Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract."
7.	Vinblastine (Vinblastine Sulfate)FDA Link 11/01/2011 - "Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder." 01/01/1984 - "Chromosome analysis of biopsy material obtained after vinblastine pretreatment was carried out in 108 specimens from 89 patients with transitional cell carcinoma of the urinary bladder. " 08/01/1982 - "Vinblastine sulfate 0.10-0.15 mg/kg IV every week, was given to 37 patients with bidimensionally measurable, metastatic transitional cell carcinoma of the urothelial tract. " 03/01/1979 - "Three patients with advanced transitional cell carcinoma of the renal pelvis were treated with 5 mg./m.2 body surface vinblastine intravenously weekly and 130 mg./m.2 chloroethyl-cyclohexyl-nitrosourea orally with 6-week intervals. " 02/01/2000 - "Standard chemotherapy of transitional cell carcinoma of the bladder is actually the combination of cisplatine, methothrexate, vinblastine and doxorubicine (MVAC). "
8.	Paclitaxel (Taxol)FDA LinkGeneric 01/01/1997 - "The goal of this study was to determine whether paclitaxel, when given by a 2-h treatment, produces significant cytotoxic effects in human bladder transitional cell carcinoma and hence qualifies as a candidate drug for intravesical treatment. " 11/01/1994 - "Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group." 05/01/2005 - "In the present assay, we examined the in vitro effect of paclitaxel (Taxol) on the transitional cell carcinoma (TCC) cell line Hu1703He. " 01/01/1997 - "Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. " 06/01/1995 - "Preliminary response data suggest significant single-agent activity for paclitaxel in transitional cell carcinoma of the bladder. "
9.	docetaxel (Taxotere)FDA Link 06/01/2002 - "Phase II studies of single-agent docetaxel (Taxotere) yielded promising results in advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. " 05/01/1997 - "Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma." 11/01/1997 - "The present study aims to evaluate the feasibility, toxicity, and efficacy of concurrent chemotherapy with cisplatinum and docetaxel, and external radical radiotherapy for transitional cell carcinoma of urinary bladder. " 07/01/2011 - "Phase III trials showed that vinflunine increases survival in patients with advanced transitional cell carcinoma of the urothelium (TCCU) tract treated in the second-line and is as effective as docetaxel in second-line NSCLC. " 11/01/2003 - "The objectives of the current study were to evaluate the safety and efficacy of gemcitabine plus docetaxel in patients with unresectable (Stage T4 or >/= N1) metastatic or locally advanced transitional cell carcinoma (TCC) of the urothelial tract. "
10.	InterferonsIBA 12/01/1998 - "To compare the efficacy of three different doses of intravesical interferon alpha-2b (IFN alpha-2b) in reducing recurrence and progression rates in superficial grade II, transitional cell carcinoma (TCC). " 12/01/1998 - "Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma." 02/01/1997 - "To assess the intravesical efficacy of 60 million units of interferon (IFN) alpha-2b in preventing recurrences of Stage pT1 transitional cell carcinoma of the bladder, as well as to assess its local and systemic toxicity. " 06/01/1995 - "To assess the efficacy of 60 MU intravesical alpha-2b interferon (IFN) in preventing recurrence of transitional cell carcinoma of the bladder. " 01/01/1997 - "Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 07/01/2010 - "The authors evaluated the incidence of pathologic downstaging and complete remission (CR) in patients with high-grade ureteral and renal pelvic transitional cell carcinoma (TCC) (upper tract TCC) who received neoadjuvant chemotherapy followed by surgery. " 07/01/2010 - "Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma." 01/01/1997 - "In recent years, chemotherapy of metastatic transitional-cell carcinoma of the bladder has advanced from the use of individual therapeutic agents, which has effected only rare responses, to the development of multi-agent regimens, which have greatly improved both partial and complete response rates, resulting in improved local care, palliation, and; perhaps, survival. " 12/01/2007 - "In this review we analyse the current status of perioperative systemic chemotherapy in the treatment of transitional cell carcinoma (TCC) of the bladder; instead of summarizing each neoadjuvant or adjuvant clinical trial we focus on the advantages and disadvantages of both strategies on the basis of theoretical considerations, and outline a rationale for a better design of future studies to confirm the efficacy of perioperative chemotherapy in TCC." 01/01/2009 - "The object of this study was to evaluate the clinical features and the efficacy of palliative chemotherapy in advanced non-transitional cell carcinomas of the urothelial tract. "
2.	Cystectomy 01/01/1984 - "Although radical cystectomy is effective in controlling the local disease, most patients still died of metastatic transitional cell carcinoma." 03/01/2000 - "The aim of this study was to determine whether p53 is helpful in making the decision to undergo cystectomy in T1, G3 transitional cell carcinoma (TCC) of the bladder, by prospectively comparing the p53 status of bladder biopsies with the histology and p53 status of the corresponding cystectomy specimens. " 06/01/2005 - "Radical cystectomy is the gold standard treatment for transitional cell carcinoma of the bladder, and the laparoscopic approach is currently being evaluated worldwide. " 09/01/2000 - "To analyze retrospectively the efficacy of radical cystectomy alone in the treatment of transitional cell carcinoma of the bladder. " 01/01/2011 - "The study population consisted of 60 patients diagnosed with transitional cell carcinomas who underwent transurethral resection and /or radical cystectomy. "
3.	Combination Drug Therapy (Combination Chemotherapy) 09/01/1985 - "A 54-year old man with metastatic transitional cell carcinoma (grade 3) of the bladder has achieved complete remission as a result of combination chemotherapy. " 05/01/1981 - "These promising results seem to indicate the high degree of effectiveness of this combination chemotherapy against transitional cell carcinoma of the bladder." 12/01/1986 - "The three-combination chemotherapy, especially protocol II, was effective against transitional cell carcinoma of the urinary tract, but the results were not satisfactory." 08/01/1987 - "Recent data from Phase II trials in patients with advanced transitional cell carcinoma of the urothelial tract suggest combination chemotherapy regimens are inducing a higher number of complete remissions (CR), and an overall response rate between 50% and 70%. " 08/01/1982 - "Thirty patients with advanced T4 transitional cell carcinoma of the bladder were treated in a prospective randomised trial with combination chemotherapy. "
4.	Radiotherapy 09/01/2007 - "We conducted a multicenter randomized trial in the United Kingdom to determine the efficacy of radical radiotherapy in reducing the incidence of progression of pT1G3 transitional cell carcinoma of the bladder to muscle invasive disease and subsequent disease fatality. " 04/01/2008 - "Re: A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. " 09/01/2007 - "A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder." 03/01/2002 - "A preliminary study of 65 patients was made (21 transitional cell carcinoma (TCC), 36 without TCC and 8 excluded patients who received BCG therapy, endocavitary mytomicin or radiotherapy), using the BTA TRAK, cytology and cystoscopy. " 06/01/1998 - "The study included 131 patients (24 women and 107 men, median age 72 years, range 40-86) with transitional cell carcinoma (T2-T4) treated with external definitive pelvic radiotherapy between 1985 and 1994. "
5.	Immunotherapy 01/01/2000 - "Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is currently the most effective treatment for superficial transitional cell carcinoma (TCC) of the urinary bladder. " 01/01/1992 - "BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. " 01/01/2014 - "Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder." 05/01/2013 - "Collateral activity of immunotherapy with bacillus Calmette-Guérin for the treatment of non-muscle-invasive transitional cell carcinoma of the bladder: new insights." 01/01/2012 - "Nowadays, the most efficient form of intravesical immunotherapy for superficial transitional cell carcinoma of the urinary bladder is the instillation of bacillus Calmette-Guérin (BCG), proceeding from an attenuated strain of Mycobacterium bovis. "